News & Events

Press Releases

Kyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101

Kyverna Therapeutics Announces FDA Clearance of Phase 2 IND for KYV-101, a Fully Human CD19 CAR T-Cell Therapy to Treat Myasthenia Gravis

Kyverna Therapeutics Congratulates the Teams at the Universities of Bochum and Magdeburg for a Late Breaker Case Report in a Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101

Kyverna Therapeutics Congratulates Scientific Advisory Board Member Peter A. Merkel, M.D., M.P.H. on receiving the 2023 ACR Distinguished Clinical Investigator Award

Kyverna Therapeutics Hosts a CAR T-Cell Therapy Symposium in Berlin to Discuss Investigational Treatment Options in Severe Neurological Autoimmune Diseases

Kyverna Therapeutics Announces Collaboration with Charité to Fund Research into B-Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases

Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma

Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing

Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform

Kyverna Therapeutics Announces Achievement of 28-Day Post-Infusion Milestone for First U.S. Patient Dosed in Phase 1 Clinical Trial of CD19 CAR T-Cell Therapy for Lupus Nephritis

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com